Latest news with #BiomedicalCatalyst
Yahoo
4 days ago
- Health
- Yahoo
Tagomics awarded £860k grant for colorectal cancer diagnostic
Tagomics has been awarded £860,000 ($1.1m) from Innovate UK to develop a test for diagnosing early-stage colorectal cancer (CRC). The Cambridge, UK-based company said the money from the UK government innovation agency's Biomedical Catalyst programme would help fund a £1.2m project that is applying its Interlace multiomics workflow platform towards the detection of genetic and epigenetic mutations associated with CRC. This includes the development of new models for analysing patients' multiomic profiles to identify new disease biomarkers. Once the project concludes, a pilot study of the diagnostic test will be undertaken with the UK National Health Service (NHS). Led by Dr Arash Assadsangabi, consultant physician and gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank, the study will profile 250 patients suspected of having CRC to validate identified biomarkers and demonstrate multiomic profiling's efficacy in the early detection of the disease. Tagomics' chief scientific officer and co-founder, Dr Robert Neely said: 'We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting CRC at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes.' Upon completion of the project, Tagomics will look to further expand the capabilities and applications of its Interlace platform with the support of Agilent Technologies, building on an established partnership that was key to the early development of the platform, Dr Neely added. The American Cancer Society estimates that there will be 107,320 new cases of colon cancer and 46,950 new cases of rectal cancer in 2025. According to GlobalData analysis, with early detection of CRC critical in reducing the disease's mortality rate, in vitro diagnostic (IVD) tests have a critical role to play in bridging the disease's screening gap, with company's such as Guardant Health at work on developing patient-first tests to create solutions that make patient care more accessible. Guardant's SHIELD test, which was approved by the US Food and Drug Administration (FDA) as a primary screening option for CRC in 2024, is intended to detect alterations in the blood associated with CRC. "Tagomics awarded £860k grant for colorectal cancer diagnostic" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Tagomics Awarded £860k Innovate UK Biomedical Catalyst Grant for Detection of Colorectal Cancer
Grant forms part of £1.2M project to customise Tagomics' multiomic profiling platform for early detection of colorectal cancer Early detection test to be developed in collaboration with the Salford Royal NHS Foundation Trust and the Northern Care Alliance Research Collection biobank CAMBRIDGE, England, June 10, 2025--(BUSINESS WIRE)--Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has been awarded £860k Innovate UK funding as part of the Biomedical Catalyst programme for the testing and development of innovative healthcare solutions from Innovate UK, the UK's innovation agency, with the remaining funding contributed by Tagomics. The funding will support the customisation of Tagomics's InterlaceTM platform to develop a highly sensitive and specific diagnostic test for the early detection and treatment of colorectal cancer, and subsequent pilot study with the NHS. Tagomics' Interlace platform is a novel multiomics workflow that unlocks disease-associated DNA biomarkers, leveraging a unique approach to epigenetic profiling which enriches unmethylated DNA for analysis without modifying the underlying DNA sequence. The Biomedical Catalyst grant will be used to apply Interlace to the detection of genetic and epigenetic mutations associated with colorectal cancer, including the development of new models for the analysis of patient multiomic profiles and identification of new disease biomarkers. A pilot study of the diagnostic test for the early detection of colorectal cancer in a clinical patient cohort will be led by Dr Arash Assadsangabi, Consultant physician and Gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank. The study will profile 250 patients suspected of having colorectal cancer to validate identified biomarkers and demonstrate the use of multiomic profiling for early detection of disease. Dr Robert Neely, CSO and co-founder of Tagomics said: "We are delighted to have been awarded the Biomedical Catalyst grant as part of the Innovate UK programme, recognising the potential of our multiomic workflow in novel diagnostic and therapeutic technologies. We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting colorectal cancer at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes." Following successful completion of the project, Tagomics will further expand the capabilities and applications of Interlace with the support of Agilent Technologies, building on the Companies' established partnership that was key to the early development of the Interlace platform. Dr Rita Shaknovich, Chief Medical Officer at Agilent Technologies, commented: "The Biomedical Catalyst grant is a fantastic achievement for Tagomics, reflecting the enormous potential for its novel multiomics workflow in the early detection of cancers. We look forward to continuing our collaboration with Tagomics and supporting the development of new applications for the Interlace platform, which brings together the strengths of Tagomics' epigenetics platform with Agilent's SureSelect target enrichment solutions, furthering cancer research and ultimately aiming to improve patient outcomes." For more information about Tagomics, please visit: View source version on Contacts Media: Francesca Sign in to access your portfolio
Business Wire
4 days ago
- Business
- Business Wire
Tagomics Awarded £860k Innovate UK Biomedical Catalyst Grant for Detection of Colorectal Cancer
CAMBRIDGE, England--(BUSINESS WIRE)--Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has been awarded £860k Innovate UK funding as part of the Biomedical Catalyst programme for the testing and development of innovative healthcare solutions from Innovate UK, the UK's innovation agency, with the remaining funding contributed by Tagomics. The funding will support the customisation of Tagomics's Interlace TM platform to develop a highly sensitive and specific diagnostic test for the early detection and treatment of colorectal cancer, and subsequent pilot study with the NHS. Tagomics' Interlace platform is a novel multiomics workflow that unlocks disease-associated DNA biomarkers, leveraging a unique approach to epigenetic profiling which enriches unmethylated DNA for analysis without modifying the underlying DNA sequence. The Biomedical Catalyst grant will be used to apply Interlace to the detection of genetic and epigenetic mutations associated with colorectal cancer, including the development of new models for the analysis of patient multiomic profiles and identification of new disease biomarkers. A pilot study of the diagnostic test for the early detection of colorectal cancer in a clinical patient cohort will be led by Dr Arash Assadsangabi, Consultant physician and Gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank. The study will profile 250 patients suspected of having colorectal cancer to validate identified biomarkers and demonstrate the use of multiomic profiling for early detection of disease. Dr Robert Neely, CSO and co-founder of Tagomics said: 'We are delighted to have been awarded the Biomedical Catalyst grant as part of the Innovate UK programme, recognising the potential of our multiomic workflow in novel diagnostic and therapeutic technologies. We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting colorectal cancer at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes.' Following successful completion of the project, Tagomics will further expand the capabilities and applications of Interlace with the support of Agilent Technologies, building on the Companies' established partnership that was key to the early development of the Interlace platform. Dr Rita Shaknovich, Chief Medical Officer at Agilent Technologies, commented: 'The Biomedical Catalyst grant is a fantastic achievement for Tagomics, reflecting the enormous potential for its novel multiomics workflow in the early detection of cancers. We look forward to continuing our collaboration with Tagomics and supporting the development of new applications for the Interlace platform, which brings together the strengths of Tagomics' epigenetics platform with Agilent's SureSelect target enrichment solutions, furthering cancer research and ultimately aiming to improve patient outcomes.'
Yahoo
4 days ago
- Business
- Yahoo
Tagomics Awarded £860k Innovate UK Biomedical Catalyst Grant for Detection of Colorectal Cancer
Grant forms part of £1.2M project to customise Tagomics' multiomic profiling platform for early detection of colorectal cancer Early detection test to be developed in collaboration with the Salford Royal NHS Foundation Trust and the Northern Care Alliance Research Collection biobank CAMBRIDGE, England, June 10, 2025--(BUSINESS WIRE)--Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has been awarded £860k Innovate UK funding as part of the Biomedical Catalyst programme for the testing and development of innovative healthcare solutions from Innovate UK, the UK's innovation agency, with the remaining funding contributed by Tagomics. The funding will support the customisation of Tagomics's InterlaceTM platform to develop a highly sensitive and specific diagnostic test for the early detection and treatment of colorectal cancer, and subsequent pilot study with the NHS. Tagomics' Interlace platform is a novel multiomics workflow that unlocks disease-associated DNA biomarkers, leveraging a unique approach to epigenetic profiling which enriches unmethylated DNA for analysis without modifying the underlying DNA sequence. The Biomedical Catalyst grant will be used to apply Interlace to the detection of genetic and epigenetic mutations associated with colorectal cancer, including the development of new models for the analysis of patient multiomic profiles and identification of new disease biomarkers. A pilot study of the diagnostic test for the early detection of colorectal cancer in a clinical patient cohort will be led by Dr Arash Assadsangabi, Consultant physician and Gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank. The study will profile 250 patients suspected of having colorectal cancer to validate identified biomarkers and demonstrate the use of multiomic profiling for early detection of disease. Dr Robert Neely, CSO and co-founder of Tagomics said: "We are delighted to have been awarded the Biomedical Catalyst grant as part of the Innovate UK programme, recognising the potential of our multiomic workflow in novel diagnostic and therapeutic technologies. We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting colorectal cancer at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes." Following successful completion of the project, Tagomics will further expand the capabilities and applications of Interlace with the support of Agilent Technologies, building on the Companies' established partnership that was key to the early development of the Interlace platform. Dr Rita Shaknovich, Chief Medical Officer at Agilent Technologies, commented: "The Biomedical Catalyst grant is a fantastic achievement for Tagomics, reflecting the enormous potential for its novel multiomics workflow in the early detection of cancers. We look forward to continuing our collaboration with Tagomics and supporting the development of new applications for the Interlace platform, which brings together the strengths of Tagomics' epigenetics platform with Agilent's SureSelect target enrichment solutions, furthering cancer research and ultimately aiming to improve patient outcomes." For more information about Tagomics, please visit: View source version on Contacts Media: Francesca Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
